Achilles Therapeutics plc (ACHL)
NASDAQ: ACHL · IEX Real-Time Price · USD
0.889
+0.019 (2.18%)
Dec 29, 2023, 4:30 PM EST - Market closed
Company Description
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors.
The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma.
The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021.
Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.
Achilles Therapeutics plc
| Country | United Kingdom |
| Founded | 2016 |
| IPO Date | Mar 31, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 234 |
| CEO | Dr. Iraj Ali |
Contact Details
Address: 245 Hammersmith Road London, X0 W6 8PW United Kingdom | |
| Phone | 44 (0)20 8154 4600 |
| Website | achillestx.com |
Stock Details
| Ticker Symbol | ACHL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001830749 |
| CUSIP Number | 00449L102 |
| ISIN Number | US00449L1026 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Iraj Ali | Chief Executive Officer and Director |
| Dr. Karl Peggs M.D. | Founder and Chief Medical Officer |
| Dr. Mark William Lowdell BSc, FRCPath, MICR, MSc, Ph.D. | Founder |
| Dr. Charles Swanton FMEDSCI, M.D., Ph.D. | Founder |
| Dr. Sergio A. Quezada Ph.D. | Founder and Chief Scientific Officer |
| Robert Coutts | Chief Financial Officer |
| Lee M. Stern | Vice President of Investor Relations and External Communications |
| Daniel Hood | General Counsel and Company Secretary |
| Julia Wilson | Head of Communications |
| Tariq Ahmed | Vice President of People |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 13, 2023 | 6-K | Report of foreign issuer |
| Nov 1, 2023 | 144 | Filing |
| Sep 22, 2023 | 6-K | Report of foreign issuer |
| Aug 17, 2023 | 144 | Filing |
| Aug 4, 2023 | 6-K | Report of foreign issuer |
| Jun 29, 2023 | 6-K | Report of foreign issuer |
| May 10, 2023 | 6-K | Report of foreign issuer |
| Apr 24, 2023 | 6-K | Report of foreign issuer |
| Mar 8, 2023 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 7, 2023 | 20-F | Annual and transition report of foreign private issuers |